Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review

Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-mediated diseases. While their efficacy is well-established, the safety concerns associated with these agents, particularly regarding thromboembolic events (TE), remain a focus of extensive research and clinical...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Krasimir Kraev, Mariela Gencheva Geneva-Popova, Bozhidar Krasimirov Hristov, Petar Angelov Uchikov, Stanislava Dimitrova Belova-Popova, Maria Ilieva Kraeva, Yordanka Mincheva Basheva-Kraeva, Nina Staneva Stoyanova, Vesela Todorova Mitkova-Hristova, Maria Stoyanova Koleva-Ivanova, Daniela Ivova Taneva, Atanas Slavchev Ivanov
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2023-11-01
Serie:	Life
Soggetti:	JAK inhibitors immune-mediated diseases safety profile adverse events
Accesso online:	https://www.mdpi.com/2075-1729/13/12/2244
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!